Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07608796 · ClinicalTrials.gov registry record · Phase 2
JAK Signaling in Depression and Cognition in Male Football Players
A Phase 2 study, sponsored by Emory University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07608796 is a Phase 2 study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 30 participants.
The verdict
NCT07608796, a Phase 2 study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of organized football. This will be evaluated using a medication called baricitinib that blocks one aspect of inflammation.
Interventions
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07608796
The ClinicalTrials.gov registry entry for NCT07608796 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Baricitinib is the first listed.
NCT07608796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07608796 about?
NCT07608796 is a clinical study titled "JAK Signaling in Depression and Cognition in Male Football Players". This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of organized football. This will be evaluated using a medication called baricitinib that blocks one aspect of inflammation.
What is the current status of trial NCT07608796?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-06. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07608796?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT07608796?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.